about
X-ray structure and mechanism of RNA polymerase II stalled at an antineoplastic monofunctional platinum-DNA adductNew antiestrogens from a library screen of homoallylic amides, allylic amides, and C-cyclopropylalkylamides.Synthesis and biological evaluation of purealin and analogues as cytoplasmic dynein heavy chain inhibitors.Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-linksCharacterization of inhibitors of glucocorticoid receptor nuclear translocation: a model of cytoplasmic dynein-mediated cargo transport.High-content analysis of cancer-cell-specific apoptosis and inhibition of in vivo angiogenesis by synthetic (-)-pironetin and analogs.Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.A core-shell-shell nanoplatform upconverting near-infrared light at 808 nm for luminescence imaging and photodynamic therapy of cancerMonofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cellsPyrimidinone-peptoid hybrid molecules with distinct effects on molecular chaperone function and cell proliferation.Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.Self-Monitoring and Self-Delivery of Photosensitizer-Doped Nanoparticles for Highly Effective Combination Cancer Therapy in Vitro and in Vivo.Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance.Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.Organocatalytic asymmetric synthesis of 1,1-diarylethanes by transfer hydrogenation.Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.Folic acid conjugated self-assembled layered double hydroxide nanoparticles for high-efficacy-targeted drug delivery.A diamond nanoneedle array for potential high-throughput intracellular delivery.Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin.Synthesis and biological evaluation of (-)-16-normethyldictyostatin: a potent analogue of (-)-dictyostatin.Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.Multimodal Upconversion Nanoplatform with a Mitochondria-Targeted Property for Improved Photodynamic Therapy of Cancer Cells.Diamond-Nanoneedle-Array-Facilitated Intracellular Delivery and the Potential Influence on Cell Physiology.Cytotoxic (salen)ruthenium(iii) anticancer complexes exhibit different modes of cell death directed by axial ligands.Recent Progress of Upconversion in Nanostructured Materials: From Optical Tuning to Biomedical Applications.A cisplatin-loaded immuno-chemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy.A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.Upconverting near-infrared light through energy management in core-shell-shell nanoparticles.Dense diamond nanoneedle arrays for enhanced intracellular delivery of drug molecules to cell linesImproved polyvinylpyrrolidone microneedle arrays with non-stoichiometric cyclodextrinNovel Pt-loaded layered double hydroxide nanoparticles for efficient and cancer-cell specific delivery of a cisplatin prodrugA monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibitionMonochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer ProdrugSynthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial FluorideA Photocaged, Water-Oxidizing, and Nucleolus-Targeted Pt(IV) Complex with a Distinct Anticancer MechanismSynthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase InhibitorsSelf-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung CancerSynthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells
P50
Q27661393-45C332F5-5A3F-42E0-A232-1052863750E5Q33209618-12509072-AEDA-4525-9ED3-1B5C8EC58086Q33236575-DBA5A12A-42ED-402F-8619-3E9AC351099AQ33429678-05EE073E-0B8F-489D-A7BB-9ACEB4059384Q34020056-7CA5D45C-8FA4-4628-A83D-C9073341DCDEQ34235175-BF353776-8B6F-4E44-9AED-4F066C78F9BAQ34842777-FA23B3CF-F037-4209-8F85-A3F4C93CC9C3Q35672757-C80F3385-514F-4105-A35E-BC0D3B4AE8F7Q35729416-1E5F85C6-39A1-484F-8221-3069EEF87CDAQ36580588-522C58C0-F4A0-4963-AEF6-47C3DB9BBEEEQ38823861-A610E039-FDEE-4449-AD92-4EBD24BA4DD6Q38833867-1A0B8F08-883B-431F-9CD1-6CCC0C0A7F72Q38861484-2D6A609F-B788-4F35-B600-F0B403BD2269Q38889630-2679F36D-7719-46EA-8553-1EC159738224Q38931590-DD521B7A-07A3-49F4-8E89-80BC1AE70F9BQ39041190-92B03C7C-7A8C-4DDD-820E-E6DD72F50C37Q39062530-F46D432C-84AD-4103-A692-61BD41A7E0CCQ39078073-0A702877-27B2-4B9F-B3A2-01180B8AD4BAQ39187469-F71A14BB-B1A3-476A-84B8-4DDAC6BFCEE0Q40353795-46755547-B26B-4DE4-B531-B534742F5F1AQ40403669-386DA739-1FE6-428C-A2B3-BDD5663F6E74Q40862682-4EBA45E6-5E50-4F89-BE09-57D926DF232DQ46568354-4AF4E9BD-95C9-4282-9FCA-194E870206B5Q46577410-14F8383C-92E3-44D2-A18F-82E45DE1EA22Q47135597-8F6B09F0-13F5-4038-935D-16B474DF4324Q47212896-D2A463E9-E389-493D-95A4-8D305D264D32Q48511650-5A438D98-5C7E-4673-87F8-6DD3C32949C9Q50047013-926086AA-CB67-43E4-9A16-6D16033D44E5Q52970552-A61888AA-911B-4B77-80A1-D6FEC8FA35E6Q54744090-6F167082-0233-4BD4-85FE-3D3573101EA8Q62565561-9A6798CD-D51F-4D9B-8898-A851FDD0A0D8Q64445603-81816D0A-FDBB-4B21-A2F6-FE8622E6A705Q64445606-23BB77C2-156D-4843-B07B-510CF06EA6FEQ86112654-B7A96E5E-B268-4A93-8ED3-C5FCF08331BAQ88879083-B43E1F16-835E-4133-90AC-70BFF1E9CC87Q89256001-A3B93E95-0524-4AD9-827F-CB010E464AAAQ90680507-A3520BFC-ED76-458E-9BEE-D8364F72C54DQ91320909-A97DDE6D-FF2E-479C-9E62-0B08880A6BB5Q92184647-AB25A483-4654-4BB6-8511-335E89CF0EF2Q92493775-2B2CD824-D59D-4FC3-AF61-C2E0B3DD6DA2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guangyu Zhu
@ast
Guangyu Zhu
@en
Guangyu Zhu
@es
Guangyu Zhu
@nl
type
label
Guangyu Zhu
@ast
Guangyu Zhu
@en
Guangyu Zhu
@es
Guangyu Zhu
@nl
prefLabel
Guangyu Zhu
@ast
Guangyu Zhu
@en
Guangyu Zhu
@es
Guangyu Zhu
@nl
P106
P1153
55451894000
P31
P496
0000-0002-4710-7070